Zhitong Finance App News, Xianjian Technology (01302.HK) issued an announcement. On September 9, 2026, the company received an official written notice from the China Drug Administration (China Drug Administration) confirming that the LantValTM aortic valve replacement system jointly developed by the Company's subsidiary Shenzhen Jianxin Medical Technology Co., Ltd. (Jianxin Medical) and Fuwai Hospital of the Chinese Academy of Medical Sciences of the National Cardiovascular Center has entered the special review procedure for innovative medical devices by the State Drug Administration. This product is suitable for surgical treatment of patients with aortic stenosis or stenosis with incomplete closure. It is the world's first fully preinstalled dry valve design (no stitching) aortic valve replacement product. It is the company's 18th product to enter the National Drug Administration's procedure.

Zhitong Finance App News, Xianjian Technology (01302.HK) issued an announcement. On September 9, 2026, the company received an official written notice from the China Drug Administration (China Drug Administration) confirming that the LantValTM aortic valve replacement system jointly developed by the Company's subsidiary Shenzhen Jianxin Medical Technology Co., Ltd. (Jianxin Medical) and Fuwai Hospital of the Chinese Academy of Medical Sciences of the National Cardiovascular Center has entered the special review procedure for innovative medical devices by the State Drug Administration. This product is suitable for surgical treatment of patients with aortic stenosis or stenosis with incomplete closure. It is the world's first fully preinstalled dry valve design (no stitching) aortic valve replacement product. It is the company's 18th product to enter the National Drug Administration's procedure.